Tyson Foods (TSN) cuts its FY26 revenue outlook to between +1.5-2% (prev. guided +2.5-3.5%), citing additional pressure in its beef segment in Q4
Newsquawk Staff ·
Tyson Foods (TSN) cuts its FY26 revenue outlook to between +1.5-2% (prev. guided +2.5-3.5%), citing additional pressure in its beef segment in Q4.
What it means
Guidance cuts framed around a single segment rather than broad-based weakness have historically been treated by the street as a distinction that matters: company-specific cost or cycle pressure in one division tends to compress the segment multiple without automatically infecting the protein peer set, whereas a demand-side read across categories would. Beef has been the structurally pressured leg of the US protein complex for an extended period, with packers squeezed between tight cattle supply on the input side and limited ability to pass costs through, a margin dynamic that has previously forced peers to idle capacity and restructure rather than wait out the cycle. The revenue guide being trimmed while the cited driver is segment margin pressure raises the question of whether the cut is volume-led or mix-led, and how it sits against the EBITDA outlook, which is the line the street actually anchors on for this name. Prior form with TSN is that guidance revisions have tended to cluster, with one trim followed by further refinement rather than a clean reset. Follow-ons worth noting are management commentary on cattle availability and packer margins on the call, any capacity actions, and read-across to peers with beef exposure.
Sources
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL
- Moonshot AI unveils 2.8tln-parameter Kimi K3.1 Pro model; says it beats Opus 5.5 and GPT-6 Astra on long-horizon coding tasks and scores top marks on SWE Marathon and agent benchmarks; pledges open weights for the 3tln-class model by November 4th
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 2027
Related headlines
- OpenAI reveals plans for an in-house exabyte-scale storage system3 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter3 hours ago
- Upside in Penguin Solutions (PEGN) attributed to M&A chatter - UNCONFIRMED 3 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability4 hours ago
- US President Trump says Elon Musk will not do anything wrong regarding access to Starlink (SPCX) in Ukraine4 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)4 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed4 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce5 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders6 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer6 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation6 hours ago
- American Express (AXP) to cut 5% of jobs6 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM6 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years7 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months8 hours ago